GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Kenvue Inc (NYSE:KVUE) » Definitions » ROCE %

KVUE (Kenvue) ROCE % : 3.02% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Kenvue ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kenvue's annualized ROCE % for the quarter that ended in Jun. 2024 was 3.02%.


Kenvue ROCE % Historical Data

The historical data trend for Kenvue's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kenvue ROCE % Chart

Kenvue Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
- 13.78 12.84 11.16 11.14

Kenvue Quarterly Data
Dec19 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.32 12.41 10.13 9.60 3.02

Kenvue ROCE % Calculation

Kenvue's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=2548/( ( (27316 - 3926) + (27851 - 5481) )/ 2 )
=2548/( (23390+22370)/ 2 )
=2548/22880
=11.14 %

Kenvue's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2024 )  (Q: Mar. 2024 )(Q: Jun. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2024 )  (Q: Mar. 2024 )(Q: Jun. 2024 )
=628/( ( (27283 - 6166) + (26443 - 5937) )/ 2 )
=628/( ( 21117 + 20506 )/ 2 )
=628/20811.5
=3.02 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kenvue  (NYSE:KVUE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Kenvue ROCE % Related Terms

Thank you for viewing the detailed overview of Kenvue's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kenvue Business Description

Traded in Other Exchanges
Address
199 Grandview Road, Skillman, NJ, USA, 08558
Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
Executives
Allison Richard E Jr director 30 FRANK LLOYD WRIGHT DR, ANN ARBOR MI 48105
Seemantini Godbole director 1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117
Bing Xie officer: Group President, Asia Pacific 199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Donna Lorenson officer: Chief Corp Affairs Officer 199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Matthew Orlando officer: General Counsel 199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Luani Alvarado officer: Chief People Officer 199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Jan Meurer officer: Chief Growth Officer 199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Carlton Lawson officer: Group President, EMEA 199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Caroline Tillett officer: Chief Scientific Officer 199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Bernardo Tavares officer: Chief Tech & Data Officer 199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Tamara Franklin director 107 STONE CLIFF ROAD, PRINCETON NJ 08540
Betsy D Holden director DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kathy Widmer officer: Group President, NALA C/O ELIZABETH ARDEN, INC., 2400 S.W. 145 AVENUE, MIRAMAR FL 33027
Michael E Sneed director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Joseph J Wolk director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933